Page 11234..1020..»

BioLife Solutions CryoStor Cell Freeze Media Used in Mayo Clinic Safety and Feasibility Study of Umbilical Cord Blood …

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Go here to read the rest:
BioLife Solutions CryoStor Cell Freeze Media Used in Mayo Clinic Safety and Feasibility Study of Umbilical Cord Blood …

Recommendation and review posted by Bethany Smith

Ask Dr. K: Bone marrow can save a life – Tue, 03 Mar 2015 PST

Anthony L. Komaroff M.D.

DEAR DOCTOR K: I have leukemia. Thankfully, a family member was a bone marrow match. Can you tell me what to expect during my bone marrow transplantprocedure?

DEAR READER: A bone marrow transplant can be a life-saving treatment. To understand how it works, you need to understand how blood cells are created. And what leukemiais.

Your blood contains red and white blood cells. There are several types of white blood cells, which are a key part of your immune system. All your blood cells are made by blood stem cells, which live primarily in the spongy center of

You have viewed 20 free articles or blogs allowed within a 30-day period. FREE registration is now required for uninterrupted access.

S-R Media, The Spokesman-Review and Spokesman.com are happy to assist you. Contact Customer Service by email or call 800-338-8801

DEAR DOCTOR K: I have leukemia. Thankfully, a family member was a bone marrow match. Can you tell me what to expect during my bone marrow transplantprocedure?

DEAR READER: A bone marrow transplant can be a life-saving treatment. To understand how it works, you need to understand how blood cells are created. And what leukemiais.

Your blood contains red and white blood cells. There are several types of white blood cells, which are a key part of your immune system. All your blood cells are made by blood stem cells, which live primarily in the spongy center of your bigbones.

In the years before you got leukemia, each of your blood cells was programmed to live for a while, and then to die only to be replaced by new, youngcells.

Visit link:
Ask Dr. K: Bone marrow can save a life – Tue, 03 Mar 2015 PST

Recommendation and review posted by Bethany Smith

Texas Woman Finds Answer for MS in Her Own Stem Cells

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

More:
Texas Woman Finds Answer for MS in Her Own Stem Cells

Recommendation and review posted by Bethany Smith

Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow …

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

More:
Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow …

Recommendation and review posted by Bethany Smith

Research and Markets: Global RNAi Market Report 2015 – Technologies, Markets and Companies 2014-2024

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/27gqxk/rnai) has announced the addition of Jain PharmaBiotech’s new report “RNAi – Technologies, Markets and Companies” to their offering.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

RNAi can be rationally designed to block the expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Research at academic centers that is relevant to RNAi-based therapeutics is mentioned.

Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2014 to 2024. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 233 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 35 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 38 tables and 12 figures.

Key Topics Covered:

Executive Summary

1. Technologies for suppressing gene function

2. RNAi Technologies

Read more from the original source:
Research and Markets: Global RNAi Market Report 2015 – Technologies, Markets and Companies 2014-2024

Recommendation and review posted by Bethany Smith

Global RNAi Market Report 2015 – Technologies, Markets and Companies 2014-2024

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

More here:
Global RNAi Market Report 2015 – Technologies, Markets and Companies 2014-2024

Recommendation and review posted by Bethany Smith

Taconic Biosciences Support Helps to Advance Rare Disease Research

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Read more from the original source:
Taconic Biosciences Support Helps to Advance Rare Disease Research

Recommendation and review posted by Bethany Smith

Research and Markets: Personalized Medicine Market Report – Scientific and Commercial Aspects 2014-2024

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

See more here:
Research and Markets: Personalized Medicine Market Report – Scientific and Commercial Aspects 2014-2024

Recommendation and review posted by Bethany Smith

Personalized Medicine Market Report 2015 – Scientific and Commercial Aspects 2014-2024

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Original post:
Personalized Medicine Market Report 2015 – Scientific and Commercial Aspects 2014-2024

Recommendation and review posted by Bethany Smith

Mammals are more like their fathers genetically

Although we inherit equal amounts of genetic mutations from our parents – the mutations that make us who we are and not some other person – we actually "use" more of the DNA that we inherit from our dads, said the team from the University of North Carolina's school of medicine. "This is an exceptional finding that opens the door to an entirely new area of exploration in human genetics," said …

Follow this link:
Mammals are more like their fathers genetically

Recommendation and review posted by Bethany Smith

Global Personalized Medicine Market Report 2015 – Scientific and Commercial Aspects 2014-2024

DUBLIN, Mar. 03, 2015 /PRNewswire/ –Research and Markets

(http://www.researchandmarkets.com/research/s3s3t8/personalized) has announced the addition of Jain PharmaBiotech’s new report “Personalized Medicine – Scientific and Commercial Aspects” to their offering.

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2020.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2014-2024.

Profiles of 311 companies involved in developing technologies for personalized medicines, along with 565 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 73 tables and 25 figures.

Key Topics Covered:

Part I: Scientific & Commercial Aspects

View original post here:
Global Personalized Medicine Market Report 2015 – Scientific and Commercial Aspects 2014-2024

Recommendation and review posted by Bethany Smith

MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Read more:
MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy

Recommendation and review posted by Bethany Smith

Patrick Sullivan: Why care about psychiatric genetics? – Video



Patrick Sullivan: Why care about psychiatric genetics?
A Stockholm Psychiatry Lecture held at Karolinska Institutet Feb 3 2015 by Prof. Patrick F Sullivan, UNC and KI. More lectures at https://www.youtube.com/Psy…

By: PsychiatryLectures

Visit link:
Patrick Sullivan: Why care about psychiatric genetics? – Video

Recommendation and review posted by Bethany Smith

Myriad Genetics to Present at the Barclays Global Healthcare Conference

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

More:
Myriad Genetics to Present at the Barclays Global Healthcare Conference

Recommendation and review posted by Bethany Smith

Research and Markets: Global Gene Therapy Market Report 2015-2025

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Continued here:
Research and Markets: Global Gene Therapy Market Report 2015-2025

Recommendation and review posted by Bethany Smith

Gene Therapy Market to be Worth over USD 10 Billion by 2025, Predicts Roots Analysis

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

See the original post:
Gene Therapy Market to be Worth over USD 10 Billion by 2025, Predicts Roots Analysis

Recommendation and review posted by Bethany Smith

Research and Markets: Gene Therapy Market Report 2015 – Technologies, Markets and Companies

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Link:
Research and Markets: Gene Therapy Market Report 2015 – Technologies, Markets and Companies

Recommendation and review posted by Bethany Smith

Gene Therapy Market Report 2014-2024 – Technologies, Markets and Companies

DUBLIN, Mar. 03, 2015 /PRNewswire/ –Research and Markets

(http://www.researchandmarkets.com/research/gxqhg9/gene_therapy) has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy – Technologies, Markets and Companies” to their offering.

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2014, over 2050 clinical trials have been completed, are ongoing or have been approved worldwide.A breakdown of these trials is shown according to the geographical areas and applications.

Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy.

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2014-2024. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets

The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 75 tables and 15 figures.

Profiles of 181 companies involved in developing gene therapy are presented along with 223 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade.

Key Topics Covered:

More:
Gene Therapy Market Report 2014-2024 – Technologies, Markets and Companies

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market Report 2015-2025 – Extensive Study on the Marketed and Pipeline Gene Therapies

DUBLIN, Mar. 03, 2015 /PRNewswire/ –Research and Markets

(http://www.researchandmarkets.com/research/rcv4lq/gene_therapy) has announced the addition of the “Gene Therapy Market, 2015 – 2025″ report to their offering.

The “Gene Therapy Market, 2015-2025″ report provides an extensive study on the marketed and pipeline gene therapies. A lot of research has been carried out in this field for over a decade but there are only five approved therapies (four available in Asian markets; one approved in the EU). There are many promising therapies which are currently being developed worldwide; the approach is likely to result in several commercial success stories in the foreseen future. The report covers various aspects, such as key players, marketed gene therapy products, products in clinical / pre-clinical research, associated ethical issues, likely future developments and upcoming opportunities for a variety of stakeholders.

Several disorders that arise inside the body are a result of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or delete the genes causing a particular disease is known as gene therapy. Although gene therapy has not contributed significantly to the global pharmaceutical market yet, it is anticipated to grow at a fast pace over the next decade.

Gendicine, developed by SiBiono GeneTech, was the foremost gene therapy that entered market in 2004 in China. Since then four more therapies have received approval in China, Philippines, Russia and the EU. This number for approved / marketed therapies seems weak at present; however, the strong and highly populated pipeline holds tremendous potential. There are 12 gene therapies in late stage of clinical development for the treatment of cancer, ocular and cardiovascular disorders.

There are several concerns that remain to be answered; examples include insertional mutagenesis, treatment of multigene disorders, curbing the risk of immune reactions, eugenics, high cost of therapy and ethical concerns related to making alterations at the genetic level. Despite this, gene therapy does offer a ray of hope for patients who either have no treatment options or show no benefits with drugs that are currently available. Such a benefit far outweighs any disadvantages that may be associated with this upcoming therapeutic field.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

Read the original:
Global Gene Therapy Market Report 2015-2025 – Extensive Study on the Marketed and Pipeline Gene Therapies

Recommendation and review posted by Bethany Smith

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

Excerpt from:
BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

Recommendation and review posted by Bethany Smith

Hunger-controlling neurons made from skin cells

Washington, March 2 (IANS) In a pioneering feat, researchers have successfully converted adult human skin cells into neurons of the type that regulate appetite.To make the neurons, human skin cells were first genetically reprogrammed to become induced pluripotent stem (iPS) cells. Like natural stem cells, iPS cells are capable of developing into any kind of adult cell when given a specific set …

The rest is here:
Hunger-controlling neurons made from skin cells

Recommendation and review posted by Bethany Smith

Arthritis Suffers Have a New Hope for Pain Relief – Video



Arthritis Suffers Have a New Hope for Pain Relief
Arthritis Joint Pain: (541) 716-6469 https://plus.google.com/+ColumbiaPainManagementPCHoodRiver/ Arthritis Joint Pain suffers have a new hope for a pain free life. Dr Rigert talks about…

By: Trey Rigert

View post:
Arthritis Suffers Have a New Hope for Pain Relief – Video

Recommendation and review posted by Bethany Smith

Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next …

Home Mail Search News Sports Finance Weather Games Answers Screen Flickr Mobile More Celebrity Movies Music TV Groups Health Style Beauty Food Parenting Makers Tech Shopping Travel Autos Homes Install the new Firefox Skip to Navigation Skip to Main content Skip to Right rail Sign In Mail Help Account Info Help Suggestions

View original post here:
Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next …

Recommendation and review posted by Bethany Smith

Mutation may cause early loss of sperm supply

Brown University biologists have determined how the loss of a gene in male mice results in the premature exhaustion of their fertility. Their fundamental new insights into the complex process of sperm generation may have direct applications to a similar loss of fertility in men.

What the team discovered is that the loss of the gene that makes the protein TAF4b causes a deficit in the number of progenitor cells at an embryonic stage of a male mouse’s reproductive development. Lacking those important precursor cells means that the mice struggle to develop a robust stem cell infrastructure to sustain sperm production for the long term. The affected mice are fertile at first, but quickly deplete the limited sperm supply that they can generate.

“What’s fascinating about these mice is they can reproduce,” said Richard Freiman, senior author of the new study in the journal Stem Cells. “Mice can usually reproduce until they are two years old, but these mice can only reproduce until they are four months old.”

TAF4b is a protein that affects how genes are regulated and transcribed, and its absence has profound impacts on the reproductive system. In previous work, Freiman’s research group has shown that female mice without TAF4b are totally infertile and that their ovaries age prematurely. But in experiments with males, led by lab members Lindsay Lovasco and Eric Gustafson, the effect proved more subtle.

Sperm generation follows from a complex chain of events that the research shows begins before a male mouse is even born. In their experiments, the team compared the development of mice with and without the TAF4b gene. In mice with TAF4b, progenitor cells for sperm in the male embryo arise and proliferate normally, laying the groundwork in the testes for a robust pool of spermatogonial stem cells to develop. Those stem cells are the ones that produce a renewable supply of sperm. Without TAF4b, there were fewer progenitor cells and consequently fewer stem cells. They still produce sperm at first, but they can’t renew production for the long haul. Ultimately the testes, which develop normally, become unproductive and atrophy.

What’s not yet clear from the research is why the process fades out rather than just continuing, albeit at a very low level of productivity. One possibility is the low supply of spermatogonial stem cells drives the body to invest all its meager resources in immediate sperm production, leaving none of the stem cells in a more flexible state that can perpetually renew the supply. Another possibility is that regardless of supply, TAF4b is simply needed to see the renewal process through, for instance by maintaining some stem cells in their regenerative state.

Four Turkish brothers

Not only do humans have a gene for TAF4b, but a coincidental study last year in the Journal of Medical Genetics provides evidence that it also matters for sperm count. That research reported that four Turkish brothers who carried a mutation in the TAF4b gene had low sperm counts. Their mutation was in the same region of their gene as the one Freiman’s team generated in the mice.

“The human implications are very exciting,” he said. “It is possible that those men, as teenagers, were able to make functional sperm.”

Certainly more research is needed, Freiman said, but if TAF4b mutation plays out in men the way it plays out in mice, his hope is that detecting the mutation in teenage boys could allow doctors to freeze their sperm so that when they are older and want to have children, they could draw on that banked supply.

Go here to see the original:
Mutation may cause early loss of sperm supply

Recommendation and review posted by Bethany Smith

Italy study finds HIV's 'hiding places' – update

Trieste team’s breakthrough could lead to new AIDS drugs

(ANSA) – Trieste, March 2 – A group of researchers at Trieste’s International Centre for Genetic Engineering and Biotechnology (ICGEB) has found the “dens” where HIV cells hide until they become “invisible”. The breakthrough, which could lead to the development of new AIDS drugs, was made possible after the team, led by Professor Mauro Giacca, photographed the structure of HIV lymphoid cell nuclei. The study was published on Tuesday on the website of highly respected journal Nature. The AIDS virus manages to insert its DNA into the cells that it infects to become part of their genetic makeup. But up to now why the virus decides to combine with only some of the 20,000 human genes and how it manages to hide from medicines inside these genes had been a mystery.

Read the original here:
Italy study finds HIV's 'hiding places' – update

Recommendation and review posted by Bethany Smith


Archives